Aimmune Therapeutics Inc (NASDAQ:AIMT) hit a new 52-week low during trading on Thursday . The stock traded as low as $24.56 and last traded at $25.30, with a volume of 5694 shares traded. The stock had previously closed at $24.85.

AIMT has been the topic of several research analyst reports. ValuEngine lowered shares of Aimmune Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Friday, September 7th. BidaskClub lowered shares of Aimmune Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Tuesday, September 11th. Stifel Nicolaus initiated coverage on shares of Aimmune Therapeutics in a research report on Thursday, September 13th. They set a “hold” rating and a $33.00 target price on the stock. Zacks Investment Research upgraded shares of Aimmune Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, July 24th. Finally, Credit Suisse Group set a $40.00 target price on shares of Aimmune Therapeutics and gave the stock a “buy” rating in a research report on Monday, August 13th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and nine have issued a buy rating to the stock. Aimmune Therapeutics currently has an average rating of “Buy” and an average price target of $50.90.

The stock has a market capitalization of $1.60 billion, a P/E ratio of -10.10 and a beta of -0.26.

Aimmune Therapeutics (NASDAQ:AIMT) last released its quarterly earnings data on Wednesday, August 8th. The biotechnology company reported ($0.91) EPS for the quarter, missing the consensus estimate of ($0.86) by ($0.05). Equities analysts forecast that Aimmune Therapeutics Inc will post -3.63 earnings per share for the current fiscal year.

Institutional investors have recently added to or reduced their stakes in the stock. Tiverton Asset Management LLC purchased a new stake in shares of Aimmune Therapeutics in the 2nd quarter worth about $145,000. Ardsley Advisory Partners purchased a new stake in shares of Aimmune Therapeutics in the 2nd quarter worth about $202,000. Xact Kapitalforvaltning AB purchased a new stake in shares of Aimmune Therapeutics in the 1st quarter worth about $207,000. Atria Investments LLC purchased a new stake in shares of Aimmune Therapeutics in the 3rd quarter worth about $213,000. Finally, WINTON GROUP Ltd purchased a new stake in shares of Aimmune Therapeutics in the 1st quarter worth about $262,000. Institutional investors and hedge funds own 78.15% of the company’s stock.

About Aimmune Therapeutics (NASDAQ:AIMT)

Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy.

Featured Article: Fundamental Analysis – How It Helps Investors

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.